Introduction
On June 3, 2026, the International Council for Harmonisation (ICH) finalized Annex 2 of E6(R3), completing the modernization of Good Clinical Practice (GCP). While the release of Annex 1 in 2025 established the core framework for interventional trials, Annex 2 introduces important considerations for applying GCP to decentralized trials, pragmatic study designs, and real-world data.
Where Annex 2 Fits Within E6(R3)
The updated E6(R3) guideline is structured into three components:
- GCP Principles – Foundational ethical and scientific standards
- Annex 1 – Core guidance for traditional interventional trials
- Annex 2 – Additional considerations for modern, non-traditional trial designs
Annex 2 is not a standalone framework. Instead, it extends existing GCP principles to ensure they remain applicable as clinical trials evolve beyond traditional, site-based models.
Key Components of Annex 2
Annex 2 focuses on how GCP should be applied in more flexible and technology-enabled trial environments.
Decentralized Trial Elements
For the first time, GCP guidance formally addresses clinical trial activities conducted outside traditional investigator sites. These may include remote interactions, home-based care, and digital tools for data collection.
This reflects the growing adoption of decentralized and hybrid trial models designed to improve accessibility and participant engagement.
Pragmatic Clinical Trial Design
Annex 2 supports trial designs that more closely align with routine clinical practice. These approaches may involve broader eligibility criteria, streamlined data collection, and integration into real-world care settings.
The goal is to generate results that better reflect actual patient populations and treatment environments.
Use of Real-World Data (RWD)
The guideline introduces additional considerations for incorporating data from sources such as electronic health records, registries, and claims databases.
Sponsors are expected to ensure that real-world data used in clinical trials is:
- Fit for purpose
- Reliable and traceable
- Appropriately governed, particularly when managed by third parties
Risk-Based and Proportionate Oversight
Annex 2 reinforces the shift toward a more flexible, risk-based approach to clinical trial oversight. This includes:
- Applying quality-by-design principles
- Scaling oversight based on trial complexity and risk
- Focusing on factors that are critical to participant safety and data integrity
Annex 1 vs. Annex 2: Key Differences
Annex 1 and Annex 2 are designed to work together, but they serve different purposes:
- Annex 1 establishes the operational framework for traditional interventional trials, including roles, responsibilities, and core requirements.
- Annex 2 extends that framework to newer trial designs, including decentralized, pragmatic, and data-driven approaches.
In practical terms:
- Annex 1 defines how trials are typically conducted.
- Annex 2 explains how those expectations apply when trial designs evolve.
What Changed From the 2024 Draft?
ICH released a draft version of Annex 2 in 2024. The final version adopted in June 2026 introduces relatively few structural changes but provides greater clarity in several areas. These include:
- Oversight of real-world data sources
- Data governance and access
- Participant-centered trial design
- Management of safety information from multiple data streams
The final guidance reinforces expectations rather than introducing an entirely new framework.
Regulatory Considerations
While Annex 2 has reached Step 4 adoption within the ICH process, regulatory adoption remains pending in key regions.
The FDA has not yet formally adopted Annex 2. The European Medicines Agency (EMA) has also not yet adopted the guideline. Adoption is anticipated, but no official timelines have been announced.
Why Annex 2 Matters
Annex 2 reflects a broader shift in clinical research. Traditional GCP guidance was developed for trials that were:
- Conducted at investigator sites
- Highly controlled
- Limited in data sources and technologies
Today’s clinical trials increasingly involve:
- Remote participation and digital tools
- Integration with routine healthcare
- Expanded use of real-world data
Annex 2 ensures that GCP remains relevant as these approaches become more common, while maintaining a consistent focus on:
- Participant safety
- Data integrity
- Scientific rigor
Final Takeaway
The release of Annex 2 completes the ICH E6(R3) framework and marks a significant step toward aligning global GCP standards with modern clinical trial practices. For organizations, the next step is practical implementation:
- Review protocols and standard operating procedures
- Evaluate decentralized and hybrid trial capabilities.
- Strengthen data governance and oversight processes.
As clinical trial design continues to evolve, Annex 2 clearly signals where regulatory expectations are heading.
